https://www.selleckchem.com/pr....oducts/FK-506-(Tacro
The patient had a complete response to treatment endoscopically, 9months after the last administration of nivolumab. After that, there was no recurrence of the cancer, despite there being no treatment for 5months. It was suggested that the therapeutic effect of nivolumab could be maintained for a long period after discontinuation of its administration. In addition, a correlation has been reported between the treatment efficacy and immune-related adverse events associated with nivolumab. The synergistic effect of the sustaine
Like
Comment
Share
